XORTX Therapeutics, a company that develops therapies to inhibit the production of uric acid, has applied for listing on the Nasdaq.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.22 |
|---|---|
| 52-week range | $1.09 - $7.00 |
| 50-day moving average | $1.58 |
| 200-day moving average | $2.33 |
| Wall St. target price | $12.17 |
| PE ratio | 10.5 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.12 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.22 from 2024-11-22
| 1 week (2024-11-19) | -6.23% |
|---|---|
| 1 month (2024-10-25) | -21.29% |
| 3 months (2024-08-26) | 0.83% |
| 6 months (2024-05-24) | -52.71% |
| 1 year (2023-11-24) | -58.22% |
|---|---|
| 2 years (2022-11-25) | -98.44% |
| 3 years (2021-11-26) | 191.16 |
| 5 years (2019-11-25) | 6,389.36% |
Valuing XORTX Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XORTX Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
XORTX Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, XORTX Therapeutics shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, XORTX Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -33.14% |
| Return on equity TTM | -29.36% |
| Profit margin | 0% |
| Book value | $2.32 |
| Market Capitalization | $4.3 million |
TTM: trailing 12 months
We're not expecting XORTX Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
XORTX Therapeutics's shares were split on a 1:9 basis on 13 November 2023 . So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XORTX Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for XORTX Therapeutics shares which in turn could have impacted XORTX Therapeutics's share price.
Over the last 12 months, XORTX Therapeutics's shares have ranged in value from as little as $1.09 up to $7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XORTX Therapeutics's is -0.207. This would suggest that XORTX Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, XORTX Therapeutics has bucked the trend.
To put XORTX Therapeutics's beta into context you can compare it against those of similar companies.
XORTX Therapeutics Inc. , a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.